Related Experiment Video
Updated: Mar 29, 2026
09:04
Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods
Published on: September 10, 2018
10.2K
Novel targeted bladder drug-delivery systems: a review
Martino Maria Zacchè1, Sushma Srikrishna1, Linda Cardozo1
1Department of Urogynaecology, King's College Hospital, London, UK.
Research and Reports in Urology
|December 10, 2015
Summary
Novel drug-delivery systems (DDSs) enhance bladder drug efficacy and reduce side effects. These systems improve intravesical drug delivery (IDD) for conditions like overactive bladder and cancer.
Area of Science:
- Pharmaceutics and Drug Delivery
- Urology and Bladder Therapeutics
Background:
- Effective drug delivery to the bladder is crucial for treating various bladder conditions.
- Systemic drug administration faces challenges like metabolism and limited bladder exposure.
- Intravesical drug delivery (IDD) is hindered by urine washout and the urothelial barrier.
Purpose of the Study:
- To review novel drug-delivery systems (DDSs) for treating bladder disorders.
- To discuss strategies for both systemic and local drug delivery to the bladder.
- To highlight advancements in nanotechnology and gene therapy for bladder conditions.
Main Methods:
- Review of current literature on drug-delivery systems for bladder conditions.
- Focus on novel formulations, nanocarriers, hydrogels, intravesical devices, and gene therapy.
- Discussion of systemic versus local delivery rationales and challenges.
Main Results:
- DDSs are essential for controlling drug release rate, time, and location in the bladder.
- Novel DDSs improve drug bioavailability, therapeutic effects, and patient compliance.
- Various DDS approaches show promise for overactive bladder, interstitial cystitis, bladder cancer, and UTIs.
Conclusions:
- Drug-delivery systems offer significant potential to overcome IDD challenges.
- Nanotechnology and gene therapy represent future frontiers in bladder disorder treatment.
- Optimized DDSs can enhance treatment efficacy and patient outcomes for bladder conditions.
Related Concept Videos
01:24Modified-Release Drug Delivery Systems: Site-Targeted
96
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
96
01:21Intrauterine Drug Delivery Systems
127
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
127
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
109
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
109
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
89
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
89
01:23Modified-Release Drug Delivery Systems: Classification
250
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
250
01:26Oral Drug Delivery Systems: Continuous-Release Systems
208
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
208